Klaus Schwarz has been heading ESTEVE in Germany for the past few months. He has many years of extensive experience in the pharmaceutical and medical technology sector, expertise in bringing medical products to market, a comprehensive understanding of healthcare and marketing as well as sales training techniques.

After positions at leading pharma companies where he worked both nationally and internationally, Schwarz is now looking forward to his new professional challenge: "There is still a lot to do in specialized therapeutic areas. We want to add value and contribute to the preservation of the healthcare system through comprehensive solutions ranging from specialized medicine to support for doctors and patients. ESTEVE is committed to advancing in innovation to improve people's life, we want to become a reliable partner for doctors and patients and make a name for ourselves as an innovative employer in the industry. Together, this will allow us to build on our strengths."

Riemser is now ESTEVE

The acquisition of Riemser was an important step for ESTEVE in its drive to internationalize the business and thus become a leading player in the field of specialty therapeutics. Germany is the company's largest non-Spanish affiliate and plays a central role in this respect.

RIEMSER Pharma GmbH has now officially become ESTEVE Pharmaceuticals GmbH to increase international brand coherence without losing its proximity to and focus on patients' needs in local markets.

ESTEVE's vision is to be a benchmark company in the field of specialized medicine, with proprietary products that provide answers to patients' unmet medical needs, and with a global presence in key markets.

ESTEVE Germany's portfolio includes prescription drugs for the treatment of serious diseases in the therapeutic areas of oncology, infectiology, neurology, cardiovascular, dermatology, and ophthalmology.

A responsible and socially committed company

ESTEVE has been serving healthcare for more than 90 years. Its corporate sustainability strategy is based on three key areas (environment, people and business) with the same focus: sustainability and care. ESTEVE is also committed to the 2030 Agenda and the Sustainable Development Goals.

Its commitment to innovation has been clearly reflected in the recent approval of Seglentis® by the FDA (U.S. Food and Drug Administration). It is an innovative product comprising a co-crystal form of celecoxib (an anti-inflammatory) and tramadol (an analgesic) for the treatment of acute pain in adults.^1-3

In the words of Klaus Schwarz: "Innovation and sustainability are key to our becoming a leading healthcare company because taking care of people, taking care of our patients' needs, is our raison d'être".

References
1. Expert Opinion on Investigational Drugs. 2019;28(5):399-409.
2. Journal of Pain Research. 2019;12:2679-2689.
3. Crystal Growth & Design. 2017;17(4):1884-1892 and 2019;19(6):3172-3182.